- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04318626
The Influence of [18F]PMPBB3 and [18F]THK5351 PET Distribution Patterns on Post-stroke Cognitive Impairment
Background and objects: Neuroinflammation is an active process detectable in the earliest stages of the neurodegeneration pathway. On the other hand, significant neuroinflammation, such as reactive astrocytosis, can also be observed after cerebral ischemic injury. [18F]THK5351 can monitor the neuroinflammatory process due to its high affinity to astrogliosis, and [18F]PMPBB3 is the novel tau protein radiotracer without significant off-target binding to MAO-B. The investigators hypothesize that the neuroinflammation after acute stroke may induce the tau protein accumulation. In the current proposal, our aims are to 1) explore the interaction between neuroinflammation and tau protein accumulation in acute stroke patients by applying both the [18F]PMPBB3 and [18F]THK5351 PET images and 2) determine their influence on the longterm stroke outcome and cognitive performance.
Method: The prospective project plans to recruit 2 groups of participants: one is patients with first-ever acute stroke (Group A, n=50), and the other is healthy people as the control group (Group B, n=30). Within 3 weeks of stroke, [18F]THK5351 and [18F]PMPBB3 PET will be done for imaging cerebral neuroinflammation and tau protein distribution. Brain MRI for obtaining structural and functional information will be done within 3 weeks and 3 months after stroke. Clinical and cognitive outcome will be evaluated at week 3 and months 3 and 12. In addition, APOE genotyping and carotid ultrasound will be performed as well. By obtaining the neuroimaging information, such as severity of white matter change and infarction, cortical and hippocampal atrophy, and SUVRs of [18F]THK5351 and [18F]PMPBB3 PET, the study will be able to investigate the complex interaction between neuroinflammation and tau protein accumulation after stroke, and also evaluate their influence on structural changes, stroke outcome and cognitive performance. Group comparisons will be performed using the Chi-square test, independent t test, Mann-Whitney U test, and multiple linear regression, where appropriate.
Anticipation: In this project, the investigators will be able to identify the distribution patterns of neuroinflammation and tau protein accumulation after actue stroke. Secondly, the investigators expect that the presence of neuroinflammation and tau protein accumulation will interfere with the functional connectivity. Finally, the investigators expect that the extent of neuroinflammation and tau protein is correlated with stroke outcome and post-stroke cognitive impairment.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Huang Kuo-Lun, M.D.
- Phone Number: 8340 +886-3-3281200
- Email: drkuolun@cgmh.org.tw
Study Contact Backup
- Name: Chen Jing-Fang
- Phone Number: 8413 +886-3-3281200
- Email: tp6tp6fg@gmail.com
Study Locations
-
-
Guishan
-
Taoyuan, Guishan, Taiwan, 333
- Recruiting
- Department of Neurology, Chang-Gung memorial Hospital
-
Contact:
- Huang Kuo-Lun, M.D.
- Phone Number: 8340 +886-3-3281200
- Email: drkuolun@cgmh.org.tw
-
Contact:
- Chen Jing-Fang
- Phone Number: 8413 +886-3-3281200
- Email: tp6tp6fg@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion criteria for acute stroke/TIA patients (Group A, n=50)
- Males or females with age >= 20 years old.
- Having acute cerebral stroke or transient ischemic attack in recent 1 month.
- Female subjects of childbearing potential must practice effective contraception during the - Provision of signed informed consent from the subject and the subject's legally
- The subject has an appropriate caregiver capable of accompanying the subject, if necessary.
Inclusion criteria for healthy controls (Group B, n = 30)
- Males or females with age >= 20 years old
- Without history of cerebral stroke or transient ischemic attack
- Without history of mild cognitive impairment or dementia
- Ability to participate in cognitive and neuroimaging assessments
- Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
- Provision of signed informed consent
Exclusion Criteria:
Exclusion criteria for acute stroke/TIA patients (Group A, n = 50)
- Presence of dementia diagnosis before the index stroke or at the initial screening
- History of vascular MCI (VaMCI)
- The Chinese version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score >=104 at the initial screening 45.
- Life expectancy less than 1 year.
- Clinically significant abnormal laboratory values.
- Clinically significant or unstable medical or psychiatric illness.
- Epilepsy history.
- Cognitive impairment resulting from trauma or brain damage.
- Substance abuse or alcoholism in the past 3 months.
- General MRI, and / or PET exclusion criteria.
- Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
- History of allergy to 18F-labelled radionucleic agents, such as [18F]PMPBB3 or [18F]THK5351.
- Subjects having high risks for the study according to the PI discretion.
Exclusion criteria for healthy controls (Group B, n = 30)
- The Chinese version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score >=104 at the initial screening 45.
- Life expectancy less than 1 year.
- Clinically significant abnormal laboratory values.
- Clinically significant or unstable medical or psychiatric illness.
- Epilepsy history.
- Cognitive impairment resulting from trauma or brain damage.
- Substance abuse or alcoholism in the past 3 months.
- General MRI, and / or PET exclusion criteria.
- Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
- History of allergy to 18F-labelled radionucleic agents, such as [18F]PMPBB3 or [18F]THK5351.
- Subjects having high risks for the study according to the PI discretion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: PMPBB3
|
F-18 PMPBB3 PET Imaging
F-18 THK5351 PET Imaging
|
Other: THK
|
F-18 PMPBB3 PET Imaging
F-18 THK5351 PET Imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CDR score of cognition deteriorating group and stable group
Time Frame: through study completion, an average of 1 year
|
The CDR is a 5-point scale (0、0.5、1、2、3) used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care. The necessary information to make each rating is obtained through a semi-structured interview of the patient and a reliable informant or collateral source (e.g., family member). Global score 0 = Normal、0.5 = Very Mild Dementia、1 = Mild Dementia、2 = Moderate Dementia、3 = Severe Dementia. The cognition deteriorating group is defined as CDR score declines from 0 or 0.5 at Month 3 to >=1 at Month 12. The cognition stable group is defined as CDR score remains at 0 or 0.5 at Month 12. |
through study completion, an average of 1 year
|
PET imaging positive and negative conditions
Time Frame: through study completion, an average of 1 year
|
PET images are visually assessed by independent raters, who are nuclear medicine doctors and blinded to all clinical and diagnostic information.
The raters classify each scan as 0-1 (no significant uptake)、2 (suspicious uptake)、3-4 (significant uptake).
The score >= 2 is deemed as positive condition.
|
through study completion, an average of 1 year
|
Correlation between Neuroimaging factors and CDR-SB condition
Time Frame: through study completion, an average of 1 year
|
Neuroimaging continuous variables will be first examined for their collinearity, determined as variance inflation factor (VIF) of 2 or more.
The approach suggested by Zuur et al is to calculate VIFs for each parameter in the model, and if they are larger than some cutoff, sequentially drop the predictor with the largest VIF, recalculate, and repeat until all values are below the cutoff of 2^68.
Variables showing moderate to significant inter-group difference (P < 0.10) will be selected for the logistic regression analysis (CDR-SB increase > 1 and conversion to dementia as the dependent variables).
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201802299A0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroinflammation
-
PfizerCompleted
-
Europainclinics z.ú.East Slovak Institute for Cardiovascular DiseasesRecruiting
-
Mayo ClinicEnrolling by invitation
-
Prof. Daniele ZullinoNot yet recruiting
-
VA Office of Research and DevelopmentOregon Health and Science University; Portland VA Medical CenterRecruitingMethamphetamine-dependenceUnited States
-
Karolinska University HospitalKarolinska InstitutetCompletedNeuroinflammationSweden
-
Chang Gung Memorial HospitalRecruitingThe Association of Postoperative Cognitive Dysfunction With Glymphatic Function and Neuroinflammation | The Association of Postoperative Cognitive Dysfunction With CSF Metabolomic ChangeTaiwan
-
University of Alabama at BirminghamCompleted
-
Columbia UniversityNational Institute on Aging (NIA)Active, not recruitingInflammation | Memory LossUnited States
-
University of Alabama at BirminghamActive, not recruitingMyocardial InfarctionUnited States
Clinical Trials on PMPBB3
-
Chang Gung Memorial HospitalRecruitingVascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal DementiaTaiwan
-
Chang Gung Memorial HospitalRecruitingAlzheimer's DiseaseTaiwan
-
Chang Gung Memorial HospitalUnknown
-
Chang Gung Memorial HospitalCompletedFrontotemporal Dementia | Progressive Supranuclear Palsy | Alzheimer's Disease | Vascular Cognitive Impairment | Cortical Basal SyndromeTaiwan
-
National Taiwan University HospitalRecruitingTau Distributions in Patients With Tauopathy Using APN-1607 PET ScanTaiwan
-
Chang Gung Memorial HospitalRecruitingProgressive Supranuclear PalsyTaiwan